JP2024525697A - 鳥類における抗体干渉の克服 - Google Patents

鳥類における抗体干渉の克服 Download PDF

Info

Publication number
JP2024525697A
JP2024525697A JP2024501558A JP2024501558A JP2024525697A JP 2024525697 A JP2024525697 A JP 2024525697A JP 2024501558 A JP2024501558 A JP 2024501558A JP 2024501558 A JP2024501558 A JP 2024501558A JP 2024525697 A JP2024525697 A JP 2024525697A
Authority
JP
Japan
Prior art keywords
antigen
protein
recombinant
recombinant protein
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525697A5 (https=
Inventor
ヴァン・ハルテン，マリア・コルネリア・ヴィルヘルミナ
イクバル，ムニル
シュレスタ，アンギタ
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2024525697A publication Critical patent/JP2024525697A/ja
Publication of JP2024525697A5 publication Critical patent/JP2024525697A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024501558A 2021-07-13 2022-07-12 鳥類における抗体干渉の克服 Pending JP2024525697A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21185334.6 2021-07-13
EP21185334 2021-07-13
PCT/EP2022/069513 WO2023285489A1 (en) 2021-07-13 2022-07-12 Overcoming antibody-interference in avians

Publications (2)

Publication Number Publication Date
JP2024525697A true JP2024525697A (ja) 2024-07-12
JP2024525697A5 JP2024525697A5 (https=) 2025-09-24

Family

ID=76920583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501558A Pending JP2024525697A (ja) 2021-07-13 2022-07-12 鳥類における抗体干渉の克服

Country Status (6)

Country Link
US (1) US20250009868A1 (https=)
EP (1) EP4370150A1 (https=)
JP (1) JP2024525697A (https=)
CN (1) CN117881422A (https=)
MX (1) MX2024000544A (https=)
WO (1) WO2023285489A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
JP5432703B2 (ja) 2006-03-15 2014-03-05 インターベツト・インターナシヨナル・ベー・ベー 組み換えモノネガウイルス目ウイルスベクター
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
CN103370079B (zh) 2010-10-18 2016-08-10 英特维特国际股份有限公司 针对家禽中禽流感的火鸡疱疹病毒作为载体的疫苗
US9012424B2 (en) 2011-05-27 2015-04-21 20Med Therapeutics B.V. Nanogels
US10428316B2 (en) 2014-12-04 2019-10-01 Intervet Inc. Immortalised chicken embryo fibroblasts
JP2018527395A (ja) 2015-09-30 2018-09-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 改良モジュール型抗原移送分子及び動物におけるその使用
MX2020005584A (es) 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
GB202016954D0 (en) * 2020-10-26 2020-12-09 Pirbright Inst Vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AVIAN DISEASE, vol. 60, JPN5025004396, 2016, pages 191 - 201, ISSN: 0005802728 *
JOURNAL OF IMMUNOLOGY, vol. VOL.179, NR.8, JPN5025004406, 2007, pages 5117 - 5125, ISSN: 0005802727 *
VACCINE, vol. VOL.28, NR.23, JPN5025004395, 2010, pages 3936 - 3943, ISSN: 0005802726 *
VACCINES, vol. VOL.6, NR.4, JPN5025004398, 2018, pages 75 - 1, ISSN: 0005802725 *

Also Published As

Publication number Publication date
EP4370150A1 (en) 2024-05-22
US20250009868A1 (en) 2025-01-09
WO2023285489A1 (en) 2023-01-19
MX2024000544A (es) 2024-04-09
CN117881422A (zh) 2024-04-12

Similar Documents

Publication Publication Date Title
JP5913316B2 (ja) ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
CN107250353B (zh) 二价猪流感病毒疫苗
JP7696960B2 (ja) レプリコン粒子および油性アジュバントによるワクチン接種
JP2012522516A (ja) ニューカッスル病ウイルスをベクターとするトリワクチン
JP2020529195A (ja) セネカウイルスａ免疫原性組成物およびその方法
AU2009328621A1 (en) Methods and compositions for use of a coccidiosis vaccine
JP2018523993A (ja) Ｐｒｒｓｖ微量タンパク質含有組換えウイルスベクター並びにその作製及び使用方法
JP7467027B2 (ja) 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
CN101421302A (zh) 针对禽流感病毒的嵌合疫苗抗原
KR102154794B1 (ko) 조류 인플루엔자 바이러스 h9n2의 표면항원을 발현하는 뉴캣슬병 바이러스 발현 시스템 및 이를 이용한 조류 백신
US20230372467A1 (en) Using fungal constructs to produce viral protein antigens
US8883123B2 (en) Use of vaccines for the treatment/prevention of the transmission of pathogens
BR112014020025B1 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
JP5735121B2 (ja) インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン
KR20180096786A (ko) M hyo 다가 백신 및 이의 용도
KR102154795B1 (ko) 조류 인플루엔자 바이러스 h5n6의 표면항원을 발현하는 뉴캣슬병 바이러스 발현 시스템 및 이를 이용한 조류 백신
KR102154796B1 (ko) 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
JP2024540290A (ja) ヘマグルチニン及びノイラミニダーゼを含むハイブリッド多価インフルエンザワクチン及びそれを使用する方法
US9913896B2 (en) Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease)
JP2024525697A (ja) 鳥類における抗体干渉の克服
KR20120131725A (ko) 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
KR20240170836A (ko) 로타바이러스에 대한 백신접종에 유용한 면역원성 조성물
Shrestha Enhancing protective efficacy of avian influenza vaccines through targeted delivery of protective antigens to chicken immune cells
KR20180041724A (ko) Fcv 재조합 백신 및 그의 용도
EP4210740A1 (en) Ha stem vaccine for ha antibody-positive targets

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224